Large-scale, multi-country real-world evidence (RWE) studies—including in Central Nervous System (CNS) indications—have the ...

After losing ground in commercial clinical trials in recent years, the UK has now turned a corner and is once again taking a ...

Nanoelectronics specialist Imec will demonstrate a miniaturised, ingestible sensor device today that can monitor ...

Guidance on the new policy from the Department for Science, Innovation and Technology (DSIT) notes that qualifying for ...

Pfizer has joined the ranks of companies developing cancer drugs that target both PD-1 and VEGF – one of the hottest drug ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

Research with patients shows that they have particular needs at specific stages, from diagnosis to longer-term disease management, that pharma and technology could address. In the crowded type 2 ...

Meeting the demand for clinically relevant neurodegenerative treatments requires a paradigm shift in how central nervous system (CNS) clinical trials have been designed and executed. Four years ...

In March, the UK marked Prostate Cancer Awareness Month - a period dedicated to boosting recognition and tackling stigma of a cancer that affects approximately one in eight men nationwide.

The Trump administration has intervened in a long-running lawsuit over the abortion pill mifepristone, asking a federal court judge to dismiss a lawsuit that could have restricted access to the drug.

Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 billion. The acquisition – which was confirmed to be in the final stages ...

Johnson & Johnson has its first regulatory approval for FcRn blocker Imaavy, getting a green light in the US for the would-be blockbuster as a treatment for generalised myasthenia gravis (gMG).